Symptomatic cases, UK
https://covid.joinzoe.com/data
https://covid.joinzoe.com/post/covid-numbers-tumble
Down 27 % on the week
Government figures 10 times lower
UK R-value = 0.8
England, 0.8
Wales, 0.9
Scotland, 0.9.
One in 27 people in the UK currently symptomatic
BA.1 BA.2 symptoms
BA.2 probably generate more mild symptoms
BA.2 lower severity
XE, not currently a big concern
ONS
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticlecumulativeincidenceofthenumberofpeoplewhohavetestedpositiveforcovid19uk/22april2022
Cumulative percentage, tested positive, survey
N = 535,116
27th April 2020 to 11th February 2022
70.7% in England (38.5 million people)
56.0% in Wales (1.7 million people)
72.2% in Northern Ireland (1.3 million people)
51.5% in Scotland (2.7 million people)
Risk of reinfection
10 times higher in Omicron times (20 December 2021 to 20 March 2022)
Compared with the period when the Delta variant was most common (17 May to 19 December 2021).
Risk of death
Risk of death involving Omicron variant was 67% lower than the Delta variant of COVID-19
Antibodies
Self-reported long COVID
1.8 million people (2.8% of the population)
As of 3 April 2022
73% symptoms at least 12 weeks
44% at least one year
Features
Fatigue, 51%
Shortness of breath, 33%
Loss of sense of smell, 26%
Difficulty concentrating, 23%
Symptoms adversely affected the day-to-day activities, 67%)
In double-vaccinated people
Self-reported long COVID was almost twice as common after Delta than after Omicron BA.1 infections
Antibody levels
Antibodies and Immunity – how do they relate to one another?
At or above the 179 ng/ml (16 and older)
98.8% in England
98.7% in Wales
99.0% in Northern Ireland
98.9% in Scotland
Antibody level of 800 ng/ml
95.4% in England
95.6% in Wales
94.4% in Northern Ireland
94.7% in Scotland
Source